APAC Regulatory Roundup: Infectious Disease A Common Theme As COVID Lingers
Diverse Policy, Regulatory Activity
A roundup of key regulatory and policy developments in the Asia-Pacific in the first half of the year reveals broad developments across the region's diverse markets, although there seemed to be a common thread - a renewed focus on infectious diseases amid the lingering impact of the pandemic and the emergence of new threats.
You may also be interested in...
GSK discontinues Cervarix in India as part of portfolio rationalization efforts against the backdrop of the arrival of Serum’s 'affordable' quadrivalent HPV vaccine. The heat is also believed to be on the UK drugmaker’s pneumococcal vaccine Synflorix in the country.
Serum Institute will supply initial doses of NVX-CoV2373 in the US, but late approvals have meant Novavax's vaccine is facing weak demand and surplus stocks in other parts of the world. Meanwhile, Serum has also secured a nod in India for the first indigenously-developed HPV vaccine, also the fifth globally.
In an era of increasing patient participation, digital health tools and ubiquitous social media use in China, several potential compliance risks should be on the radar while conducting clinical study, patient recruitment and commercial activities, caution legal experts in a new report.